Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities

Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone

Read more at globenewswire.com